Long-term echocardiographic assessment of descendants of gestational breast cancer patients exposed to anthracycline-based chemotherapy

2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
M Oneto Fernandez ◽  
R Gonzalez-Manzanares ◽  
C Garcia-Duran ◽  
D Mesa Rubio ◽  
M Ruiz Ortiz ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Control Group ◽  
Case Group ◽  
Breast Cancer Patients ◽  
Third Trimester ◽  
Common Cancer ◽  
Echocardiographic Parameters ◽  
Echocardiographic Assessment ◽  
Anthracycline Dose

Abstract Background Breast cancer is the most common cancer in women and the leading cause of cancer death in women. Although gestational breast cancer (GBC) accounts only for a small amount of diagnosis, the incidence is increasing due to delayed childbearing. Treating GBC is a significant challenge, having to maintain a balance between effective treatment for the patient and safety for the descendants. Anthracycline-based chemotherapy (AC) remains to be the systemic treatment of choice in many GBC patients. Although AC in GBC appears to be safe for the descendants, data on the long-term cardiotoxic effects of AC are scarce. Purpose To evaluate long-term cardiotoxicity on descendants of GBC patients exposed to AC during pregnancy or breastfeeding. Methods We retrospectively recruited descendants of GBC patients and classified them according to AC exposure (case group and non-exposed control group). We performed a thorough echocardiographic assessment. Results We identified 7 GBC patients that received AC during pregnancy (n=6) or breastfeeding (n=1). All of them were diagnosed during the second or third trimester. Median cumulative anthracycline dose was 508mg/m2. A total of 8 cases and 5 controls were recruited. Median age at echocardiographic assessment was 10 years in cases and 8 years in controls. None of them had known prior cardiac disease. Echocardiographic parameters were within normal values in both groups (Table 1). Conclusion A long-term echocardiographic assessment showed no abnormalities in a series of descendants of GBC exposed to AC during pregnancy or breastfeeding. This study may contribute to a better understanding of the safety for the descendants of AC during pregnancy or breastfeeding. Funding Acknowledgement Type of funding source: None

scholarly journals Anthracycline-Induced Cardiotoxicity in Breast Cancer Patients from Southern Sri Lanka: An Echocardiographic Analysis

2020 ◽  
Vol 2020 ◽  
pp. 1-8
Author(s):  
Jayasinghe Arachchige Nirosha Sandamali ◽  
Ruwani Punyakanthi Hewawasam ◽  
Madappuli Arachchige Chaminda Sri Sampath Fernando ◽  
Kamani Ayoma Perera Wijewardana Jayatilaka ◽  
Ranji Duleep Madurawe ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Left Ventricular ◽  
Breast Cancer Patients ◽  
Anthracycline Therapy ◽  
Echocardiographic Parameters ◽  
Chemotherapy Dose ◽  
Anthracycline Dose ◽  
Anthracycline Chemotherapy

Anthracycline-induced cardiotoxicity has never been investigated in Sri Lanka. Therefore, this study was conducted to determine the prevalence of anthracycline-induced cardiotoxicity in breast cancer patients using echocardiographic findings. A prospective cohort study was performed. All newly diagnosed breast cancer patients who were administered with anthracycline and cyclophosphamide (AC schedule) for the first time were enrolled in the study. In the hospital setting, anthracycline is administered only as a combination therapy, and only this combination was selected to limit the effect of other cardiotoxic chemotherapy agents. Records of echocardiography were obtained: one day before anthracycline chemotherapy (baseline), one day after the first chemotherapy dose, one day after the last chemotherapy dose, and six months after the completion of anthracycline chemotherapy. Following parameters were recorded from the echocardiography results: ejection fraction (EF, %), fractioning shortening (FS, %), posterior wall thickness, left ventricle (PWT, mm), the thickness of interventricular septum (IVS, mm), left ventricular end-diastolic diameter (LVEDD, mm), and left ventricular end-systolic diameter (LVESD, mm). Statistical analysis of the echocardiography results was performed using ANOVA at four stages. A p value <0.05 was considered significant. Subclinical cardiac dysfunction was defined as a fall of EF >10% during the follow-up echocardiography. There was no significant change ( p > 0.05 ) between the baseline echocardiographic parameters and one day after the 1st anthracycline dose. However, significant differences ( p < 0.05 ) were observed between the baseline echocardiographic parameters and one day after the last anthracycline dose and six months after the completion of anthracycline therapy with a gradual and progressive deterioration in functional parameters including EF, FS, PWT, and IVS over time. There were 65 patients out of 196 (33.16%) who developed subclinical cardiac dysfunction six months after the completion of anthracycline chemotherapy. The prevalence of subclinical anthracycline-induced cardiotoxicity was relatively higher in these patients. An equation was also developed based on left ventricular ejection fraction (LVEF) to predict the anthracycline-induced cardiotoxicity of a patient six months after the completion of anthracycline chemotherapy. We believe that this will help in the monitoring of patients who undergo anthracycline therapy for cardiotoxicity. It is recommended to carry out a long-term follow-up to detect early-onset chronic progressive cardiotoxicity in all patients who were treated with anthracycline therapy.

Safety and long-term maintenance of anti-HER2 immunity following booster inoculations of the E75 breast cancer vaccine.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 2529-2529
Author(s):  
Raetasha Sheavette Dabney ◽  
Diane F Hale ◽  
Timothy J Vreeland ◽  
Guy T. Clifton ◽  
Alan K. Sears ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Vaccine ◽  
Peptide Vaccine ◽  
Control Group ◽  
Breast Cancer Patients ◽  
Recurrence Rates ◽  
Specific Immunity

2529 Background: We have completed accrual and are in the follow up portion of phase I/II clinical trials evaluating the E75 HER2 peptide vaccine. E75 has been proven safe, capable of stimulating HER2 immunity, and effective in decreasing breast cancer recurrence rates. During the conduct of this trial, it was noted that E75-specific immunity waned after the Primary Vaccine Series (PVS) which corresponded with late recurrences. To maintain long-term immunity, a voluntary booster program was started. Here we present analysis of the booster inoculations. Methods: The trial enrolled node-positive or high-risk, node-negative breast cancer patients (pts) with tumors expressing any level of HER2 (IHC 1-3+). HLA-A2/A3+ pts comprised the vaccine group (VG), HLA-A2/A3- pts were followed as the control group (CG). The VG received 4-6 monthly inoculations of E75+GM-CSF. Volunteer booster program pts (BG) received inoculations every 6 months after the PVS. Pts were monitored for toxicities, in vivo responses by local reactions (LR) and DTH, and in vitro responses measured by enumeration of E75 specific cytotoxic T lymphocytes. Results: 53 pts received at least 1 booster, 34 received 2, 24 three, 20 four, 12 five, and 8 at least 6. 24% of pts had no local toxicity, 73% Grade 1 (G1), 3% G2. 74% had no systemic toxicity, 35% G1, 1% G2. LRs increased significantly from the initial vaccine (R1) during PVS to each booster (B) (R1: 59.5±3.1 v B1: 89.2±3.3, p<0.001; v B2: 95.15±5, p<0.001; v B3: 86.63±5.5, p<0.001; v B4: 83.26±4.6, p=<0.001; v B5: 80.67±6.7, p=0.006; v B6: 78.75±9.4, p=0.04). Dimer values increased from the end of PVS to each post-booster value (pre B1:1.29±0.25 v post B1: 1.46±0.38; post B2: 1.41±0.4; post B3: 1.84±0.35; post B4: 2.23±0.4; post B5:1.94±0.31; post B6: 2.73±0.09, p=0.02). At median 60 months, the recurrence rate for BG was 3.8% vs 18.9% in the CG (p=0.01). Conclusions: Booster inoculations are well-tolerated and appear to assist in the maintenance of long term peptide-specific immunity. Boosted pts have improved recurrence rates. Based on the success of this program, we have incorporated the practice of booster inoculations in our current cancer vaccine trials.

scholarly journals Dermatoglyphy in Breast Cancer Patients: A Systematic Review

2021 ◽  
Vol 5 (11) ◽  
pp. 1014-1029
Author(s):  
Rara Inggarsih ◽  
Akhyar Dyni Zakyah ◽  
Lusia Hayati ◽  
Joko Marwoto ◽  
Septi Purnamasari ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Systematic Review ◽  
Cancer Patients ◽  
Breast Development ◽  
Control Group ◽  
Cancer Genes ◽  
Breast Cancer Patients ◽  
Brca1 And Brca2 ◽  
History Of

Background. Breast cancer is one of the four types of cancer among women and is the most frequently diagnosed in most countries. Breast cancer occurs due to DNA damage and genetic mutations affected by exposure to estrogen, inheritance of damaged DNA, or pro-cancer genes such as BRCA1 and BRCA2. Therefore, a family history of ovarian cancer or breast cancer increases the risk of developing breast cancer. The embryo of the breast develops around the age of 6 weeks of pregnancy. Similar to breast development, fingerprint patterns also develop during the 6-13 weeks of pregnancy. Thus, the genetic message contained in the genome occurred during that period and was reflected in the dermatoglyphic pattern.Methods. The literature search was systematically used using PubMed, Cochran, Google scholar, and other Gray literature between 2010-2020. Of the 69 publications identified, 21 met the criteria and were included in the review. The review is carried out following the provisions of PRISMA (Preferred Reporting Items for Systematic Review).Results. This systematic review showed fairly consistent findings in breast cancer patients who tended to have more whorl fingerprint patterns and larger ATD angles. For radial loops, ulnar loops and arches were minor compared to the control group potential as an initial screening tool in at-risk groups.Conclusion. Long-term and follow-up studies with larger sample sizes in various ethnicities are needed to validate dermatoglyphics in anthropometric measurements as a promising marker of breast cancer.

scholarly journals Prevention of Prolonged Lymphorrhea in Minor Pectoral Myoplasty in Women after Breast Cancer Surgery: Anatomical and Physiological Aspects

2020 ◽  
Vol 13 (2) ◽  
pp. 98-102
Author(s):  
Alexandr Vladimirovich Aseev ◽  
Dmitry Anatolyevich Maximov ◽  
Olga Olegovna Suleymanova
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Dead Space ◽  
Radical Mastectomy ◽  
Radical Resection ◽  
Breast Cancer Surgery ◽  
Control Group ◽  
Case Group ◽  
Breast Cancer Patients ◽  
Simultaneous Application

Introduction. Surgery remains the main method of treatment for breast cancer patients. However, in surgery a large number of lymphatic vessels are crossed which inevitably leads to a lymph flow damage. The article discusses the problem of lymphorrhea in breast cancer patients after the radical mastectomy and radical resection. The aim of the study was to assess the effectiveness of minor pectoral myoplasty in the axillary region of the "dead space" for lymphorrhea prevention after radical mastectomy and radical resection.Methods. The case group included 30 patients who underwent 30 surgeries with myoplasty of pectoralis minor (Maddens radical mastectomy or radial resection) in the Tver Oncological Center at the Department of breast pathology from 2016 to 2017. The control group included 30 patients who underwent Maddens mastectomy or radical resection without myoplasty (conventional option).Results. In the case group, during the mastectomy, the patients with lymphorrhea had the drainage removed on the 5,31,2 day. The total amount of the drainage was around 235,43,6 ml. The average daily volume of the drained liquid was 47,12,7 ml. In the control group, during the radical mastectomy without myoplasty, the drainage was removed on the 12,71,4 day. The average total amount of the drained liquid was 1691,632,5 ml. The average daily drained volume was 130,32,5 ml.The patients after radical resection in the case group had the drainage removed on the 5,21,2 day. The total amount of the drained liquid in patients with lymphorrhea was 25 ml/day. The total amount of the drained liquid was 223,711,3 ml. The average daily drained volume was 44,62,3 ml. The patients after radical resection in the control group had the drainage removed on the 11,22,0 day. The average total volume of the drained liquid was 835,526,4 ml. The average daily drained volume was 69,92,2 ml.Conclusion. Application of A. Kh. Ismagilov intraoperative technique dead space closure in minor pectoral myoplasty (patent No. 2385673, issued April 10, 2010) with the simultaneous application of compression garments appears to be a simple and effective method for reducing postoperative lymphorrhea. Myoplasty was effective in reducing lymphorrhea regardless of the type of surgical intervention (radical mastectomy or radical resection). Lymphorrhea duration reduced in more than 2 times.

scholarly journals Electrocardiographic evaluation of depolarization and repolarization abnormalities in breast cancer patients with HER2-inhibitor related cardiac dysfunction

2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
T Kinoshita ◽  
H Yuzawa ◽  
R Wada ◽  
K Yano ◽  
S Yao ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Cardiac Dysfunction ◽  
Left Ventricular ◽  
Control Group ◽  
Case Group ◽  
Breast Cancer Patients ◽  
T Wave ◽  
And Control ◽  
Repolarization Abnormalities

Abstract Background The arrhythmic substrates of the myocardium such as depolarization and repolarization abnormalities are thought to reflect cardiac dysfunction prior to the morphologic left ventricular dysfunction. Activation time (AT), recovery time (RT) and T wave peek-end interval dispersion (Tpe-dispersion) are useful indicators of the arrhythmic substrate. We examined the appearance of depolarization and repolarization abnormalities in patients with cancer therapeutics-related cardiac dysfunction (CTRCD) using AT, RT and Tpe-dispersion. Methods We conducted a standardized case-control study of CTRCD with 40 patients who developed breast cancer and treated with trastuzumab (13 cases and 27 controls). We assessed the relation between electrocardiographic indexes, including AT, RT and corrected Tpe-dispersion, and CTRCD. QT intervals were measured by Fridericia method, and QT observer 3 software were used for the measurement of all electrocardiographic indexes. Results LVEF in case and control group were 45.7±8% and 69.2±6%, respectively. AT in aVR lead was significantly higher in case group compared with control (28.8±7ms vs 22.8±5ms, P=0.02). corrected Tpe-dispersion tended to be higher in case group than that of control group (43.2±19ms vs 31.9±10ms, P=0.06). QT dispersion and RT dispersion were not different between case and control group. Conclusions Our study demonstrated that AT in aVR may predict cardiac dysfunction in breast cancer patients with HER2-inhibitor related cardiac dysfunction. More detailed studies using other modalities which can detect depolarization and repolarization abnormalities, including ventricular late potentials and T wave alternans, are needed. Funding Acknowledgement Type of funding source: None

scholarly journals Single nucleotide polymorphism rs1799794 in XRCC3 gene on breast cancer patients

2021 ◽  
Vol 62 (2) ◽  
pp. 5-9
Author(s):  
Thi Thu Thao Nguyen ◽  
◽  
Thu Thuy Nguyen ◽  
Vu Viet Ha Vuong ◽  
Huy Thinh Tran ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Disease Onset ◽  
Strand Break ◽  
Control Group ◽  
Case Group ◽  
Protective Effects ◽  
Nucleotide Polymorphisms ◽  
Breast Cancer Patients ◽  
Single Nucleotide ◽  
Xrcc3 Gene

The single nucleotide polymorphisms of the XRCC3 gene including rs1799794 affect the DNA double-strand break/repair. Therefore, it plays a critical part in the initiation of carcinogenesis. This study aimed to investigate the distribution of rs1799794 and the association between rs1799794 and breast cancer risk. The study was performed in 208 Vietnamese females suffering from breast cancer and 208 age-matched normal healthy controls. DNA was extracted from whole blood whilst genotyping was conducted using PCR-RFLP. The results show that the frequency of the A and G allele in the case group are 0.575 and 0.425, in the control group are 0.548 and 0.452. The frequency of AA, AG, GG genotype in the case group are 34.6, 45.7, and 19.7%; in the control group are 33.2, 43.3, and 23.5%. AG genotype of rs1799794 associated with disease onset early of breast cancer, increasing the risk of breast cancer among those who were 45 years old and younger. The GG genotype has protective effects and reduces the risk of breast cancer in the age group ≤45 years.

scholarly journals Dermatoglyphy in Breast Cancer Patients: A Systematic Review

2021 ◽  
Vol 5 (4) ◽  
pp. 925-940
Author(s):  
Rara Inggarsih ◽  
Akhyar Dyni Zakyah ◽  
Lusia Hayati ◽  
Joko Marwoto ◽  
Septi Purnamasari ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Systematic Review ◽  
Cancer Patients ◽  
Breast Development ◽  
Control Group ◽  
Cancer Genes ◽  
Breast Cancer Patients ◽  
Brca1 And Brca2 ◽  
History Of

Background. Breast cancer is one of the four types of cancer among women and is the most frequently diagnosed in most countries. Breast cancer occurs due to DNA damage and genetic mutations affected by exposure to estrogen, inheritance of damaged DNA, or pro-cancer genes such as BRCA1 and BRCA2. Therefore, a family history of ovarian cancer or breast cancer increases the risk of developing breast cancer. The embryo of the breast develops around the age of 6 weeks of pregnancy. Similar to breast development, fingerprint patterns also develop during the 6-13 weeks of pregnancy. Thus, the genetic message contained in the genome occurred during that period and was reflected in the dermatoglyphic pattern.Methods. The literature search was systematically used using PubMed, Cochran, Google scholar, and other Gray literature between 2010-2020. Of the 69 publications identified, 21 met the criteria and were included in the review. The review is carried out following the provisions of PRISMA (Preferred Reporting Items for Systematic Review).Results. This systematic review showed fairly consistent findings in breast cancer patients who tended to have more whorl fingerprint patterns and larger ATD angles. For radial loops, ulnar loops and arches were minor compared to the control group potential as an initial screening tool in at-risk groups.Conclusion. Long-term and follow-up studies with larger sample sizes in various ethnicities are needed to validate dermatoglyphics in anthropometric measurements as a promising marker of breast cancer.

scholarly journals LIPID PROFILE AND ITS SIGNIFICANCE IN BREAST CANCER

2020 ◽  
Vol 8 (10) ◽  
pp. 1241-1248
Author(s):  
Sharmin Arif ◽  
◽  
Fauzia Abdus Samad ◽  
Syed Abdus Samad ◽  
Asif Riaz Khan ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lipid Profile ◽  
Cancer Patients ◽  
Morbidity And Mortality ◽  
Control Group ◽  
Breast Cancer Patients ◽  
Control Groups ◽  
Common Cancer ◽  
And Control ◽  
The Relationship

Background: According to WHO, breast cancer is the most common cancer in the women worldwide, soearly diagnosis is the best way to reduce its morbidity and mortality. Among various risk factors, the relationship between serum lipid profile and breast cancer is still unclear. Therefore, this study was conducted to evaluate this relationship. Methodology: Prospective, descriptive observational study with a comparative study designconducted at Fauji Foundation Hospital, Rawalpindi between November 2018 to April 2019. Results: 140 patients were divided into two groups i.e. cases and controls. Both groups were equally sub divided based on menstrual status. Independent student t-test was applied for comparison between the groups. BMI was significantly higher in the study group as compared to control group (p=0.002). Serum TG and LDL levels were higher in breast cancer patients (p= 0.032 and p=0.07 respectively). Cholesterol level was not statistically different in any group (p= >0.05). Higher HDL levels were seen in pre-menopausal cases (p=0.004) but there was no statistical difference when studied across cases and control groups. Conclusion: As breast cancer is the most common tumor in females, so early diagnosis is the key to reduce its morbidity and mortality. In this study, higher BMI, TG and LDL levels were seen in breast cancer patients as compared to controls. So, it may be concluded that BMI and dyslipidemia have some role in the etiology of breast cancer.

Sign in / Sign up

Export Citation Format

Share Document